SNCA Gene Modulation for Parkinson's Disease Diagnosis and Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating Parkinson's disease (PD) are inadequate as they only address symptoms and not the underlying cause, with no reliable or effective prevention or treatment options available, particularly for carriers of SNCA genomic variants.
Innovation Solution
Identification of SNCA-mediated genes and their modulation through transcription factor binding sites, which creates de novo recognition motifs or alters existing ones, allowing for the modulation of gene expression and activity to diagnose and treat PD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current FDA approved Parkinson's drugs are used, then symptoms can be managed to some extent, but the underlying cause of PD is not addressed and significant side effects occur
Solution Approach 1:
The patent extracts and targets specific SNCA-mediated genes (such as HERC3, HERC5, HERC6, PPM1K, PDZRN4, ABCG2) that are directly involved in PD pathogenesis, separating the treatment focus from general symptom management. This allows targeted modulation of disease-causing mechanisms while avoiding the broadside effects of conventional Parkinson's medications
Solution Approach 2:
The patent changes the treatment parameter from symptomatic relief to molecular-level gene expression modulation. By altering the expression levels of specific SNCA-mediated genes through transcription factor binding site modulation, the invention addresses the underlying biochemical causes of PD rather than merely managing symptoms
2Measurement precision
If SNCA genomic variants are identified, then risk assessment improves, but the mechanism connecting SNCA activity to localized substantia nigra degeneration remains unclear
Solution Approach 1:
The patent segments the SNCA gene's regulatory regions into specific transcription factor binding sites (such as STAT5, TCF3/4, ID4, KLF1/4/5/12, TBX4/5, MAFG, SP3, PAX2, FOXD2, FOXO4/6, MEIS1/3) that can be independently analyzed and modulated. This segmentation allows precise identification of which regulatory elements drive SNCA expression in the substantia nigra versus other brain regions
Solution Approach 2:
The patent introduces transcription factors as intermediary molecules that bridge the gap between SNCA genomic variants and localized neurodegeneration. These transcription factors bind to specific DNA sequences created or altered by SNCA variants, mediating the transcriptional regulation that leads to pathological SNCA accumulation in the substantia nigra
3Quantity of substance
If conventional research focuses on biochemical consequences of PD, then observable effects are documented, but the actual causation mechanism of PD remains unidentified
Solution Approach 1:
The patent performs preliminary action by identifying and characterizing transcription factor binding sites in SNCA genomic variants before disease progression occurs. By analyzing the regulatory DNA sequences and their transcription factor interactions in advance, the invention can establish causal mechanisms and develop preventive strategies before the full biochemical consequences of PD manifest
Data Source
AI summary
The present invention provides compositions and methods using SNCA-mediated genes and expression products thereof for diagnosis, treatment and prevention of Parkinson's disease. The present invention also relates to a method of identifying therapeutic agents to treat and diagnose Parkinson's disease based on SNCA-mediated genes.